Is Repatha (evolocumab) known to cause peripheral neuropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Repatha Known to Cause Neuropathy?

No, Repatha (evolocumab) is not known to cause peripheral neuropathy based on FDA labeling and major clinical trial data. The drug has been extensively studied in large-scale trials without any identified association with neuropathy as an adverse effect.

Evidence from FDA Labeling and Clinical Trials

The FDA-approved prescribing information for Repatha does not list neuropathy or peripheral neuropathy as a known adverse effect 1. The most commonly reported adverse reactions in clinical trials were:

  • Injection site reactions (2.1% vs 1.6% placebo in FOURIER)
  • Myalgia (0.9% in post-marketing surveillance)
  • Headache (0.4%)

Major Safety Data

FOURIER Trial (27,564 patients)

The landmark FOURIER trial, which followed patients for a median of 2.2 years, found that serious adverse events were comparable between evolocumab and placebo groups (24.8% vs 24.7%) 2. Importantly:

  • No differences in muscle-related events
  • No differences in elevations of liver function tests
  • No signal for neurocognitive events (which would be more likely to be reported than peripheral neuropathy if neurological effects were present)

Neurocognitive Safety Assessment

The EBBINGHAUS sub-study of FOURIER specifically evaluated neurological function and found no difference in cognitive function between evolocumab and placebo groups 3. While this focused on central nervous system effects, the absence of any neurological safety signals is reassuring regarding peripheral neuropathy risk.

Real-World Safety Data

A 2025 Korean post-marketing surveillance study of 539 patients found adverse drug reactions in only 2.4% of patients, with myalgia (0.9%) and headache (0.4%) being most common—no reports of neuropathy 4.

Important Context

While certain cardiovascular medications (particularly statins) can rarely cause peripheral neuropathy 5, evolocumab works through a completely different mechanism (PCSK9 inhibition) and does not share this risk profile. The drug has been studied in:

  • Over 40,000 patients across clinical trials
  • Follow-up extending to 5+ years in extension studies
  • Patients achieving very low LDL-C levels (<20 mg/dL) without neurological safety concerns 3

Clinical Bottom Line

If a patient on Repatha develops peripheral neuropathy, look for alternative causes rather than attributing it to the medication. Common culprits to investigate include:

  • Diabetes or prediabetes
  • Vitamin B12 deficiency
  • Concomitant medications (chemotherapy agents, certain antimicrobials, other cardiovascular drugs)
  • Alcohol use
  • Underlying autoimmune or hereditary neuropathies

The extensive safety database for evolocumab provides strong reassurance that neuropathy is not a recognized adverse effect of this medication 2, 3, 1, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.